← Leaderboards
Charles M. Rice
Rockefeller University
$80,497,748
Attributed
$83,583,319
Total exposure
72
Grants
58
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $83.1M · FY2005–25$100M$75M$50M$25M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$167,140,252 · 75
By mechanism
U19$82,835,876 · 7
R01$62,799,118 · 19
P01$14,220,494 · 3
R21$2,838,655 · 6
R37$2,165,603 · 1
U54$1,134,339 · 1
Top collaborators
- Sangeeta N. Bhatia5 shared
- Paul D Bieniasz2 shared
- Pamela J Bjorkman2 shared
- Marina Caskey2 shared
- Theodora Hatziioannou2 shared
- Michel C Nussenzweig2 shared
- Alexander Ploss2 shared
- George M Shaw2 shared
Most similar at Rockefeller University
Same institution · by research overlap
- Christopher T Jones$159,486
- Margaret R Macdonald$8,108,887
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsInfectionVirusHepatitis C VirusViralVirus ReplicationProteinsVirus DiseasesInsightBaseAntiviral AgentsHepatitis CIn VitroIn VivoChronicImmune ResponseResponseAnimal ModelPathogenGenomeViral RnaPathogenesisPrimary Carcinoma Of The Liver CellsAffect
Grant awards (200)
Unraveling yellow fever 17D vaccine attenuation: The role of type I interferon and innate immunity$846,776
R01 · FY2025 · AI · contact PI
Breaching the species barrier: Towards an immunocompetent HBV-susceptible mouse model$780,790
R01 · FY2025 · AI · contact PI
Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biology$738,557
R01 · FY2025 · AI · contact PI
Employing viruses to unravel the functional significance of the m5C epitranscriptome$629,355
R01 · FY2025 · AI · contact PI
Tracking SARS-CoV-2 one molecule at a time: Spatiotemporal investigation of coronavirus replication dynamics and host response in single cells in vitro and in vivo$608,868
R01 · FY2025 · AI · contact PI
TMEM41B: a pan-flavivirus and pan-coronavirus host factor with antiviral potential$608,191
R01 · FY2025 · AI · contact PI
A clear view of encephalitis: a single cell approach to determine the basis of flaviviral pathogenesis in the central nervous system$565,829
R01 · FY2025 · AI · contact PI
Unraveling yellow fever 17D vaccine attenuation: The role of type I interferon and innate immunity$846,776
R01 · FY2024 · AI · contact PI
Breaching the species barrier: Towards an immunocompetent HBV-susceptible mouse model$788,208
R01 · FY2024 · AI · contact PI
Tracking SARS-CoV-2 one molecule at a time: Spatiotemporal investigation of coronavirus replication dynamics and host response in single cells in vitro and in vivo$650,415
R01 · FY2024 · AI · contact PI
Employing viruses to unravel the functional significance of the m5C epitranscriptome$649,424
R01 · FY2024 · AI · contact PI
Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biology$611,076
R01 · FY2024 · AI · contact PI
A clear view of encephalitis: a single cell approach to determine the basis of flaviviral pathogenesis in the central nervous system$610,856
R01 · FY2024 · AI · contact PI
TMEM41B: a pan-flavivirus and pan-coronavirus host factor with antiviral potential$607,344
R01 · FY2024 · AI · contact PI
A renewable and genetically tractable human stem cell-derived multicellular platform for the study of fibrotic liver diseases$475,975
R01 · FY2024 · DK · contact PI
Elucidating the mechanism by which ADAR1 prevents autoimmunity against self RNA$211,875
R21 · FY2024 · AI · contact PI
Broad neutralization of pandemic threat coronaviruses$4,259,011
P01 · FY2023 · AI
Scientific Core: BSL3 Virology and Animal Models$983,100
P01 · FY2023 · AI · contact PI
Unraveling yellow fever 17D vaccine attenuation: The role of type I interferon and innate immunity$846,776
R01 · FY2023 · AI · contact PI
Employing viruses to unravel the functional significance of the m5C epitranscriptome$660,046
R01 · FY2023 · AI · contact PI
A clear view of encephalitis: a single cell approach to determine the basis of flaviviral pathogenesis in the central nervous system$628,189
R01 · FY2023 · AI · contact PI
Tracking SARS-CoV-2 one molecule at a time: Spatiotemporal investigation of coronavirus replication dynamics and host response in single cells in vitro and in vivo$619,267
R01 · FY2023 · AI · contact PI
Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biology$611,076
R01 · FY2023 · AI · contact PI
TMEM41B: a pan-flavivirus and pan-coronavirus host factor with antiviral potential$610,107
R01 · FY2023 · AI · contact PI
In search of an HBV cure: novel model systems and targets$594,284
R01 · FY2023 · AI · contact PI
A renewable and genetically tractable human stem cell-derived multicellular platform for the study of fibrotic liver diseases$494,315
R01 · FY2023 · DK · contact PI
Elucidating the mechanism by which ADAR1 prevents autoimmunity against self RNA$254,250
R21 · FY2023 · AI · contact PI
Metropolitan AntiViral Drug Accelerator$65,141,731
U19 · FY2022 · AI
Broad neutralization of pandemic threat coronaviruses$6,423,268
P01 · FY2022 · AI
Virology Core$5,289,678
U19 · FY2022 · AI · contact PI
Scientific Core: BSL3 Virology and Animal Models$1,454,501
P01 · FY2022 · AI · contact PI
Unraveling yellow fever 17D vaccine attenuation: The role of type I interferon and innate immunity$881,526
R01 · FY2022 · AI · contact PI
A clear view of encephalitis: a single cell approach to determine the basis of flaviviral pathogenesis in the central nervous system$681,863
R01 · FY2022 · AI · contact PI
Tracking SARS-CoV-2 one molecule at a time: Spatiotemporal investigation of coronavirus replication dynamics and host response in single cells in vitro and in vivo$637,644
R01 · FY2022 · AI · contact PI
Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biology$630,683
R01 · FY2022 · AI · contact PI
In search of an HBV cure: novel model systems and targets$594,284
R01 · FY2022 · AI · contact PI
A renewable and genetically tractable human stem cell-derived multicellular platform for the study of fibrotic liver diseases$494,315
R01 · FY2022 · DK · contact PI
TMEM41B: a pan-flavivirus and pan-coronavirus host factor with antiviral potential$460,854
R01 · FY2022 · AI · contact PI
Virology Core$219,214
P01 · FY2022 · AI · contact PI
Identification of host factors required by the tick-borne Powassan virus$211,875
R21 · FY2022 · AI · contact PI
In search of an HBV cure: novel model systems and targets$594,284
R01 · FY2021 · AI · contact PI
Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biology$565,164
R01 · FY2021 · AI · contact PI
Analysis of immunity, viral adaptation and pathogenesis in a new mouse model of HCV-related rodent hepacivirus infection$554,390
R01 · FY2021 · AI · contact PI
A renewable and genetically tractable human stem cell-derived multicellular platform for the study of fibrotic liver diseases$509,922
R01 · FY2021 · DK · contact PI
Defining therapeutic drug targets for SARS-CoV-2-specific and pan-coronavirus inhibition$483,500
R21 · FY2021 · AI · contact PI
Identification of host factors required by the tick-borne Powassan virus$254,250
R21 · FY2021 · AI · contact PI
Virology Core$220,350
P01 · FY2021 · AI · contact PI
The yellow fever vaccine saga: Defining the viral and host determinants responsible for success versus failure$741,079
R01 · FY2020 · AI · contact PI
Analysis of immunity, viral adaptation and pathogenesis in a new mouse model of HCV-related rodent hepacivirus infection$619,185
R01 · FY2020 · AI · contact PI
In search of an HBV cure: novel model systems and targets$594,284
R01 · FY2020 · AI · contact PI
Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biology$560,079
R01 · FY2020 · AI · contact PI
A systematic analysis of small RNA interactions during RNA virus infections$536,595
R01 · FY2020 · AI · contact PI
Type I interferon-stimulated genes and the antiviral immune response$531,906
R01 · FY2020 · AI · contact PI
Type I interferon-stimulated genes and the antiviral immune response$437,515
R01 · FY2020 · AI · contact PI
Virology Core$220,350
P01 · FY2020 · AI · contact PI
HEP DART 2019: Frontiers in Drug Development for Hepatology$8,500
R13 · FY2020 · AI
The yellow fever vaccine saga: Defining the viral and host determinants responsible for success versus failure$939,659
R01 · FY2019 · AI · contact PI
A systematic analysis of small RNA interactions during RNA virus infections$683,339
R01 · FY2019 · AI · contact PI
Analysis of immunity, viral adaptation and pathogenesis in a new mouse model of HCV-related rodent hepacivirus infection$624,270
R01 · FY2019 · AI · contact PI
In search of an HBV cure: novel model systems and targets$612,444
R01 · FY2019 · AI · contact PI
Type I interferon-stimulated genes and the antiviral immune response$551,494
R01 · FY2019 · AI · contact PI
Virology Core$220,350
P01 · FY2019 · AI · contact PI
The yellow fever vaccine saga: Defining the viral and host determinants responsible for success versus failure$772,861
R01 · FY2018 · AI · contact PI
Analysis of immunity, viral adaptation and pathogenesis in a new mouse model of HCV-related rodent hepacivirus infection$715,770
R01 · FY2018 · AI · contact PI
A systematic analysis of small RNA interactions during RNA virus infections$706,055
R01 · FY2018 · AI · contact PI
Type I interferon-stimulated genes and the antiviral immune response$626,686
R01 · FY2018 · AI · contact PI
Effects of Persistent Innate Immune Activation on Vaccine Efficacy$541,028
U19 · FY2018 · AI · contact PI
Virology Core$220,350
P01 · FY2018 · AI · contact PI
Host factors in innate immunity and retroelement control$211,875
R21 · FY2018 · AI · contact PI
The yellow fever vaccine saga: Defining the viral and host determinants responsible for success versus failure$798,777
R01 · FY2017 · AI · contact PI
Analysis of immunity, viral adaptation and pathogenesis in a new mouse model of HCV-related rodent hepacivirus infection$703,869
R01 · FY2017 · AI · contact PI
Type I interferon-stimulated genes and the antiviral immune response$664,588
R01 · FY2017 · AI · contact PI
Effects of Persistent Innate Immune Activation on Vaccine Efficacy$599,480
U19 · FY2017 · AI · contact PI
A systematic analysis of small RNA interactions during RNA virus infections$545,126
R01 · FY2017 · AI · contact PI
Host factors in innate immunity and retroelement control$254,250
R21 · FY2017 · AI · contact PI
The yellow fever vaccine saga: Defining the viral and host determinants responsible for success versus failure$790,963
R01 · FY2016 · AI · contact PI
Hepatitis C antivirals: Mechanism of action, combination efficacy and resistance$735,361
R01 · FY2016 · AI · contact PI
Effects of Persistent Innate Immune Activation on Vaccine Efficacy$644,149
U19 · FY2016 · AI · contact PI
Identification and characterization of cellular factors involved in HCV entry$546,673
R01 · FY2016 · AI · contact PI
A systematic analysis of small RNA interactions during RNA virus infections$539,134
R01 · FY2016 · AI · contact PI
Type I interferon-stimulated genes and the antiviral immune response$508,500
R01 · FY2016 · AI · contact PI
Type I interferon-stimulated genes and the antiviral immune response$48,285
R01 · FY2016 · AI · contact PI
Hepatitis C antivirals: Mechanism of action, combination efficacy and resistance$735,361
R01 · FY2015 · AI · contact PI
Effects of Persistent Innate Immune Activation on Vaccine Efficacy$632,104
U19 · FY2015 · AI · contact PI
Identification and characterization of cellular factors involved in HCV entry$546,673
R01 · FY2015 · AI · contact PI
Type I interferon-stimulated genes and the antiviral immune response$422,500
R01 · FY2015 · AI · contact PI
Hepatitis C antivirals: Mechanism of action, combination efficacy and resistance$735,361
R01 · FY2014 · AI · contact PI
Effects of Persistent Innate Immune Activation on Vaccine Efficacy$599,052
U19 · FY2014 · AI · contact PI
Identification and characterization of cellular factors involved in HCV entry$546,673
R01 · FY2014 · AI · contact PI
Type I interferon-stimulated genes and the antiviral immune response$422,500
R01 · FY2014 · AI · contact PI
Simianizing hepatitis C: Defining the species-tropism of a hepatotropic virus$409,772
R01 · FY2014 · AI · contact PI
Transmitted/Founder HCV clones as targets for treatment and eradication.$204,546
R21 · FY2014 · AI
Modeling human hepatotropic infections in complex tissue organoids$1,086,207
R01 · FY2013 · DK · contact PI
Hepatitis C antivirals: Mechanism of action, combination efficacy and resistance$691,240
R01 · FY2013 · AI · contact PI
Identification and characterization of cellular factors involved in HCV entry$513,873
R01 · FY2013 · AI · contact PI
Type I interferon-stimulated genes and the antiviral immune response$397,150
R01 · FY2013 · AI · contact PI
Structure and function of the HCV RNA replicase$353,659
R01 · FY2013 · CA · contact PI
Simianizing hepatitis C: Defining the species-tropism of a hepatotropic virus$353,080
R01 · FY2013 · AI · contact PI
Identification of interferon effectors that inhibit RNA virus replication$352,507
U54 · FY2013 · AI · contact PI
Transmitted/Founder HCV clones as targets for treatment and eradication.$247,296
R21 · FY2013 · AI
Modeling human hepatotropic infections in complex tissue organoids$1,110,614
R01 · FY2012 · DK · contact PI
Hepatitis C antivirals: Mechanism of action, combination efficacy and resistance$735,361
R01 · FY2012 · AI · contact PI
Identification and characterization of cellular factors involved in HCV entry$488,913
R01 · FY2012 · AI · contact PI
Type I interferon-stimulated genes and the antiviral immune response$422,500
R01 · FY2012 · AI · contact PI
Role of HCV p7 and NS2 in infectious virus production$414,092
R01 · FY2012 · AI · contact PI
Simianizing hepatitis C: Defining the species-tropism of a hepatotropic virus$409,772
R01 · FY2012 · AI · contact PI
Structure and function of the HCV RNA replicase$376,233
R01 · FY2012 · CA · contact PI
Identification of interferon effectors that inhibit RNA virus replication$352,031
U54 · FY2012 · AI · contact PI
Modeling human hepatotropic infections in complex tissue organoids$1,101,742
R01 · FY2011 · DK · contact PI
Identification of interferon effectors that inhibit RNA virus replication$429,801
U54 · FY2011 · AI · contact PI
Simianizing hepatitis C: Defining the species-tropism of a hepatotropic virus$426,849
R01 · FY2011 · AI · contact PI
Type I interferon-stimulated genes and the antiviral immune response$422,500
R01 · FY2011 · AI · contact PI
Role of HCV p7 and NS2 in infectious virus production$414,092
R01 · FY2011 · AI · contact PI
Identification and characterization of cellular factors involved in HCV entry$406,225
R01 · FY2011 · AI · contact PI
Structure and function of the HCV RNA replicase$376,233
R01 · FY2011 · CA · contact PI
HOST FACTORS ASSOCIATED WITH THE SINDBIS VIRUS RNA-DEPENDENT RNA POLYMERASE$5,214
P41 · FY2011 · RR · contact PI
INVESTIGATIONS OF THE FUNCTION OF NS4B OF HCV$1,304
P41 · FY2011 · RR · contact PI
INVESTIGATING THE FUNCTION OF NS4B OF BVDV$1,304
P41 · FY2011 · RR · contact PI
STUDY OF HCV RNA-PROTEIN INTERACTIONS$1,304
P41 · FY2011 · RR · contact PI
Modeling human hepatotropic infections in complex tissue organoids$1,126,288
R01 · FY2010 · DK · contact PI
An inbred mouse model for HCV infection, immunity andpathogenesis$494,927
RC1 · FY2010 · DK · contact PI
Simianizing hepatitis C: Defining the species-tropism of a hepatotropic virus$465,660
R01 · FY2010 · AI · contact PI
Role of HCV p7 and NS2 in infectious virus production$418,275
R01 · FY2010 · AI · contact PI
Identification and characterization of cellular factors involved in HCV entry$410,329
R01 · FY2010 · AI · contact PI
Structure and function of the HCV RNA replicase$387,869
R01 · FY2010 · CA · contact PI
FUNCTION OF G3BP$2,321
P41 · FY2010 · RR · contact PI
INVESTIGATIONS OF THE FUNCTION OF NS4B OF HCV$1,167
P41 · FY2010 · RR · contact PI
INVESTIGATING THE FUNCTION OF NS4B OF BVDV$1,167
P41 · FY2010 · RR · contact PI
STUDY OF HCV RNA-PROTEIN INTERACTIONS$1,167
P41 · FY2010 · RR · contact PI
Modeling human hepatotropic infections in complex tissue organoids$1,135,336
R01 · FY2009 · DK · contact PI
Hepatitis C: Studies of Immunity and Pathogenesis$821,545
U19 · FY2009 · AI · contact PI
Structure and function of the HCV RNA replicase$561,080
R01 · FY2009 · CA · contact PI
An inbred mouse model for HCV infection, immunity andpathogenesis$499,763
RC1 · FY2009 · DK · contact PI
Role of HCV p7 and NS2 in infectious virus production$421,250
R01 · FY2009 · AI · contact PI
Identification and characterization of cellular factors involved in HCV entry$414,473
R01 · FY2009 · AI · contact PI
Structure and function of the HCV RNA replicase$387,294
R01 · FY2009 · CA · contact PI
HCV Infection Systems and Role of Neutralizing Antibodies in Hepatitis C$308,493
U19 · FY2009 · AI · contact PI
Administrative Core$31,565
U19 · FY2009 · AI · contact PI
Hepatitis C: Studies of Immunity and Pathogenesis$4,973
U19 · FY2009 · AI · contact PI
FUNCTION OF G3BP$2,367
P41 · FY2009 · RR · contact PI
INVESTIGATING THE FUNCTION OF NS4B OF BVDV$1,190
P41 · FY2009 · RR · contact PI
STUDY OF HCV RNA-PROTEIN INTERACTIONS$1,190
P41 · FY2009 · RR · contact PI
INVESTIGATIONS OF THE FUNCTION OF NS4B OF HCV$1,190
P41 · FY2009 · RR · contact PI
Hepatitis C: Studies of Immunity and Pathogenesis$797,618
U19 · FY2008 · AI · contact PI
Role of HCV p7 and NS2 in infectious virus production$420,000
R01 · FY2008 · AI · contact PI
Identification and characterization of cellular factors involved in HCV entry$414,473
R01 · FY2008 · AI · contact PI
HCV Infection Systems and Role of Neutralizing Antibodies in Hepatitis C$299,508
U19 · FY2008 · AI · contact PI
Administrative Core$30,649
U19 · FY2008 · AI · contact PI
FUNCTION OF G3BP$2,218
P41 · FY2008 · RR · contact PI
INVESTIGATIONS OF THE FUNCTION OF NS4B OF HCV$2,218
P41 · FY2008 · RR · contact PI
NS5A PHOSPHORYLATION$1,102
P41 · FY2008 · RR · contact PI
INVESTIGATING THE FUNCTION OF NS4B OF BVDV$1,102
P41 · FY2008 · RR · contact PI
STUDY OF HCV RNA-PROTEIN INTERACTIONS$1,102
P41 · FY2008 · RR · contact PI
Hepatitis C: Studies of Immunity and Pathogenesis$789,384
U19 · FY2007 · AI · contact PI
Identification and characterization of cellular factors involved in HCV entry$422,500
R01 · FY2007 · AI · contact PI
Hepatitis C Virus-Developing Antivirals and Vaccines$376,571
R01 · FY2007 · CA · contact PI
HCV Infection Systems and Role of Neutralizing Antibodies in Hepatitis C$296,418
U19 · FY2007 · AI · contact PI
Administrative Core$30,328
U19 · FY2007 · AI · contact PI
INVESTIGATING THE FUNCTION OF NS4B OF BVDV$3,767
P41 · FY2007 · RR · contact PI
INVESTIGATIONS OF THE FUNCTION OF NS4B OF HCV$3,767
P41 · FY2007 · RR · contact PI
NS5A PHOSPHORYLATION$1,883
P41 · FY2007 · RR · contact PI
MAPPING PHOSPHORYLATION SITES IN THE NON-STRUCTURAL PROTEIN 5A FROM HEPATITUS C$1,883
P41 · FY2007 · RR · contact PI
STUDY OF HCV RNA-PROTEIN INTERACTIONS$1,883
P41 · FY2007 · RR · contact PI
Hepatitis C: Studies of Immunity and Pathogenesis$789,280
U19 · FY2006 · AI · contact PI
Hepatitis C Virus-Developing Antivirals and Vaccines$387,818
R01 · FY2006 · CA · contact PI
HCV Infection Systems and Role of Neutralizing Antibodies in Hepatitis C$286,707
U19 · FY2006 · AI · contact PI
Administrative Core$59,384
U19 · FY2006 · AI · contact PI
FLAVIVIRUS CAPSID ASSEMBLY AND VIRUS ENTRY$5,086
P41 · FY2006 · RR · contact PI
INVESTIGATING THE FUNCTION OF NS4B OF BVDV$2,466
P41 · FY2006 · RR · contact PI
INVESTIGATIONS OF THE FUNCTION OF NS4B OF HCV$2,466
P41 · FY2006 · RR · contact PI
NS5A PHOSPHORYLATION$1,233
P41 · FY2006 · RR · contact PI
STUDY OF HCV RNA-PROTEIN INTERACTIONS$1,233
P41 · FY2006 · RR · contact PI
MAPPING PHOSPHORYLATION SITES IN THE NON-STRUCTURAL PROTEIN 5A FROM HEPATITUS C$1,233
P41 · FY2006 · RR · contact PI
Hepatitis C: Studies of Immunity and Pathogenesis$848,905
U19 · FY2005 · AI
Hepatitis C Virus-Developing Antivirals and Vaccines$396,857
R01 · FY2005 · CA
MOLECULAR GENETICS OF SINDBIS VIRUS REPLICATION$375,750
R37 · FY2005 · AI
HCV Infection Systems and Role of Neutralizing Antibodies in Hepatitis C$251,675
U19 · FY2005 · AI
Administrative Core$61,004
U19 · FY2005 · AI
Conference--Drug development for Viral Hepatitis$30,000
R13 · FY2005 · AI
Viruses and Cells Gordon Conference$22,500
R13 · FY2005 · AI
FLAVIVIRUS CAPSID ASSEMBLY AND VIRUS ENTRY$5,402
P41 · FY2005 · RR
MAPPING PHOSPHORYLATION SITES IN THE NON-STRUCTURAL PROTEIN 5A FROM HEPATITUS C$3,571
P41 · FY2005 · RR
HCV PATHOGENESIS AND DENDRITIC CELL IMMUNOBIOLOGY$2,645
M01 · FY2005 · RR
INVESTIGATING THE FUNCTION OF NS4B OF BVDV$2,380
P41 · FY2005 · RR
INVESTIGATIONS OF THE FUNCTION OF NS4B OF HCV$2,380
P41 · FY2005 · RR
NS5A PHOSPHORYLATION$1,190
P41 · FY2005 · RR
HEPATITIS C: STUDIES OF IMMUNITY AND PATHOGENESIS$777,103
U19 · FY2004 · AI
Hepatitis C Virus-Developing Antivirals and Vaccines$395,975
R01 · FY2004 · CA
MOLECULAR GENETICS OF SINDBIS VIRUS REPLICATION$375,750
R37 · FY2004 · AI
Small Molecules as Research Tools for HCV Biology$252,750
R21 · FY2004 · DK
FLAVIVIRUS CAPSID ASSEMBLY AND VIRUS ENTRY$12,870
P41 · FY2004 · RR
NS5A PHOSPHORYLATION$2,345
P41 · FY2004 · RR
HCV pathogenesis and dendritic cell immunobiology$2,167
M01 · FY2004 · RR
HEPATITIS C: STUDIES OF IMMUNITY AND PATHOGENESIS$759,817
U19 · FY2003 · AI
IMMUNOTHERAPY PROTECTION &VACCINES FOR HEPATITIS C$405,730
R01 · FY2003 · CA
Hepatitis C Virus-Developing Antivirals and Vaccines$385,488
R01 · FY2003 · CA
MOLECULAR GENETICS OF SINDBIS VIRUS REPLICATION$375,750
R37 · FY2003 · AI
Small Molecules as Research Tools for HCV Biology$252,188
R21 · FY2003 · DK
HEPATITIS C: STUDIES OF IMMUNITY AND PATHOGENESIS$701,031
U19 · FY2002 · AI
IMMUNOTHERAPY PROTECTION &VACCINES FOR HEPATITIS C$394,651
R01 · FY2002 · CA